Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Lake Erie College of Osteopathic Medicine, Lake Erie, Pennsylvania, USA.
Christopher M
CM
Wolfe
W Harris
WH
Green
Armand B
AB
Cognetta
H Keith
HK
Hatfield
D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000813:Anilides; D000970:Antineoplastic Agents; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines